Showing 1421-1430 of 1576 results for "".
- Cell Types in the Eye Have Ancient Evolutionary Originshttps://modernod.com/news/cell-types-in-the-eye-have-ancient-evolutionary-origins/2482026/Karthik Shekhar of the Shekhar Lab at UC Berkeley and his colleagues raised a few eyebrows as they collected cow and pig eyes from Boston butchers, but those eyes—eventually from 17 separate species, including humans—are providing insights into the evolution of the vertebrate ret
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd/2481990/In a phase 2 study, EyePoint Pharmaceuticals’ wet AMD drug candidate demonstrated noninferiority to Eylea—with a less frequent dosing regimen. EyePoint leadership said the sustained-release implant could represent a 'paradigm-altering maintenance treatment' for patients with w
- Injectsense and Injectpower Secure $9.4M to Support Injectsense's First-in-Human Studies for Sensors that Continuously Measure IOPhttps://modernod.com/news/injectsense-and-injectpower-secure-94m-to-support-injectsenses-first-in-human-studies-for-sensors-that-continuously-measure-iop/2481973/Injectsense and sister company Injectpower, a developer of ultra-miniature solid-state microbatteries for medical applications, announced combined funding of $9.4 million to bring highly integrated autonomous implantable devices—smaller than a grai
- First Patient Dosed in Ocugen's Phase 1/2 Trial Evaluating Safety and Efficacy of OCU41OST Modifier Gene Therapy for Stargardt Diseasehttps://modernod.com/news/first-patient-dosed-in-ocugens-phase-12-trial-evaluating-safety-and-efficacy-of-ocu41ost-modifier-gene-therapy-for-stargardt-disease/2481960/Ocugen announced that the first patient has been dosed in its phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. “There is a significant unmet medical need for the approximate 35,000 patien
- Belite Bio’s Tinlarebant Studied to Treat Childhood-onset Stargardt Diseasehttps://modernod.com/news/belite-bios-tinlarebant-studied-to-treat-childhood-onset-stargardt-disease/2481950/Belite Bio presented final data from a 24-month, phase 2 study of Tinlarebant (LBS-008) in adolescent Stargardt disease (STGD1). The study—LBS-008-CT02—enrolled 12 adolescent STGD1 patients, aged 12-18 years, who completed
- Neurolens Introduces N3 VR-Based Measurement and Education Experiencehttps://modernod.com/news/neurolens-introduces-n3-vr-based-measurement-and-education-experience/2481854/Neurolens has introduced N3—a virtual reality experience designed to educate patients while measuring eye alignment. N3 provides an objective, accurate, and repeatable measurement of binocular alignment, which incorporates elements of heterophoria, fixation disparit
- Erin Powers Joins J&J Vision as Vice President of US Sales and Marketing for its Surgical Vision Portfoliohttps://modernod.com/news/erin-powers-joins-jj-vision-as-vice-president-of-us-sales-and-marketing-for-its-surgical-vision-portfolio/2481838/Johnson & Johnson announced the appointment of Erin Powers to the position of Vice President of US Sales and Marketing for its Surgical Vision portfolio. Ms. Powers will lead the US sales, marketing, and professional education teams, and will join the company within t
- Business Executive Alex Gorsky Joins Neurotech’s Board as Lead Directorhttps://modernod.com/news/business-executive-alex-gorsky-joins-neurotechs-board-as-lead-director/2481827/Neurotech Pharmaceuticals announced that Alex Gorsky has been elected to Neurotech’s board as Lead Director. Mr. Gorsky is the former Chairman and CEO of Johnson & Johnson. Under Mr. Gorsky’s leadership, Johnson & Johnson grew to become one of world’s larg
- Eye Care Charity Orbis Announces New Partnership with Heidelberg Engineeringhttps://modernod.com/news/eye-care-charity-orbis-announces-new-partnership-with-heidelberg-engineering/2481817/Orbis announced a new partnership with Heidelberg Engineering in which Heidelburg will fund crucial teaching opportunities and research—focusing on training eye care professionals around the world via Cybersight (Orbis’s telemedicine and e-learning p
- Alcon to Showcase Innovations for Eye Care Practice Success at 2023 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-innovations-for-eye-care-practice-success-at-2023-optometrys-meeting/2481682/Alcon will showcase innovations from advances in the reusable lens space to digital offerings at Optometry’s Meeting, the American Optometric Association (AOA) annual conference taking place June 21-24 in Washington, D.C. Through interactive events, Q&A’s, live demonstrations, and